Read by QxMD icon Read


Anders Rosendal Korshoej, Guilherme Bicalho Saturnino, Line Kirkegaard Rasmussen, Gorm von Oettingen, Jens Christian Hedemann Sørensen, Axel Thielscher
OBJECTIVE: The present work proposes a new clinical approach to TTFields therapy of glioblastoma. The approach combines targeted surgical skull removal (craniectomy) with TTFields therapy to enhance the induced electrical field in the underlying tumor tissue. Using computer simulations, we explore the potential of the intervention to improve the clinical efficacy of TTFields therapy of brain cancer. METHODS: We used finite element analysis to calculate the electrical field distribution in realistic head models based on MRI data from two patients: One with left cortical/subcortical glioblastoma and one with deeply seated right thalamic anaplastic astrocytoma...
2016: PloS One
A Chaudhry, D Garcia-Carracedo, Z Bomzon, H S Hershkovich, C Wenger, U Weinberg, Y Palti
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
N Urman, Z Bomzon, H S Hershkovich, U Weinberg, E Kirson, Y Palti
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Marlon G Saria, Santosh Kesari
BACKGROUND: Glioblastoma (GBM) is a highly aggressive astrocytoma with a dismal prognosis. Since 1976, only three chemotherapeutic agents have been approved for the treatment of GBM. Tumor-treating fields (TTFields) therapy, delivered via a noninvasive device, is a new therapy approved for use in patients with recurrent GBM and in combination with temozolomide for the treatment of newly diagnosed GBM. OBJECTIVES: This article reviews the mechanism of action and findings from preclinical and clinical studies supporting the use of TTFields for patients with newly diagnosed and recurrent GBM...
October 1, 2016: Clinical Journal of Oncology Nursing
Margaret A Schwartz, Lynnette Onuselogu
BACKGROUND: More than 150 years after the first description of glioma cells, patients with glioblastoma (GBM) continue to have a poor prognosis despite standard-of-care therapy. With the introduction of tumor-treating fields (TTFields) therapy for the treatment of recurrent GBM in 2011 and for newly diagnosed GBM in 2015, the opportunity to increase progression-free survival and overall survival while improving quality of life provides a welcome option. OBJECTIVES: This article describes how TTFields therapy may be used in the treatment of patients with recurrent GBM...
October 1, 2016: Clinical Journal of Oncology Nursing
Mary Elizabeth Davis
BACKGROUND: Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults. Current treatment options at diagnosis are multimodal and include surgical resection, radiation, and chemotherapy. Significant advances in the understanding of the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies for recurrent and newly diagnosed disease. Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival...
October 1, 2016: Clinical Journal of Oncology Nursing
Janlyn Murphy, Mary Ellen Bowers, Loretta Barron
BACKGROUND: After receiving U.S. Food and Drug Administration approval for the treatment of newly diagnosed glioblastoma (GBM) in 2015, following initial approval for treatment of recurrent GBM in 2011, Optune®, a device that uses tumor-treating fields (TTFields) therapy, continues to gain acceptance in the practice environment. OBJECTIVES: This article reviews how TTFields differ from traditional GBM treatment approaches and discusses the pivotal role nurses play in helping patients successfully use this therapy...
October 1, 2016: Clinical Journal of Oncology Nursing
Andreas F Hottinger, Patricia Pacheco, Roger Stupp
Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomized phase 3 trials in glioblastoma (GBM) and demonstrated to prolong progression-free survival (PFS) and overall survival (OS) when administered together with standard maintenance temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM...
October 2016: Neuro-oncology
John Trusheim, Erin Dunbar, James Battiste, Fabio Iwamoto, Nimish Mohile, Denise Damek, Daniela A Bota, Jennifer Connelly
Tumor treating fields (TTFields) are an integral treatment modality in the management of glioblastoma and extend overall survival when combined with maintenance temozolomide in newly diagnosed patients. Complexities exist regarding correct selection of imaging sequences with which to perform TTFields treatment planning. Guidelines are warranted first, to facilitate treatment planning standardization across medical disciplines and institutions, to ensure optimal TTFields delivery to the tumor and peritumoral brain zone while maximizing patient safety, and also to mitigate the risk of premature cessation of a potentially beneficial treatment...
September 15, 2016: CNS Oncology
Tali Voloshin, Mijal Munster, Roni Blatt, Anna Shteingauz, Paul C Roberts, Eva M Schmelz, Moshe Giladi, Rosa S Schneiderman, Einav Zeevi, Yaara Porat, Ze'ev Bomzon, Noa Urman, Aviran Itzhaki, Shay Cahal, Eilon D Kirson, Uri Weinberg, Yoram Palti
Long-term survival rates for advanced ovarian cancer patients have not changed appreciably over the past four decades; therefore, development of new, effective treatment modalities remains a high priority. Tumor Treating Fields (TTFields), a clinically active anticancer modality utilize low-intensity, intermediate frequency, alternating electric fields. The goal of this study was to evaluate the efficacy of combining TTFields with paclitaxel against ovarian cancer cells in vitro and in vivo. In vitro application of TTFields on human ovarian cancer cell lines led to a significant reduction in cell counts as compared to untreated cells...
December 15, 2016: International Journal of Cancer. Journal International du Cancer
Jun Li, Cangran Guo, Zhongshuai Wang, Kai Gao, Xudong Shi, Jing Liu
BACKGROUND: We proposed a method of using electrical stimulation for treatment of malignant melanoma through directly spray-printing liquid metal on skin as soft electrodes to deliver low intensity, intermediate frequency electric fields. METHODS: With patterned conductive liquid metal components on mice skin and under assistance of a signal generator, a sine wave electrical power with voltage of 5 V and 300 kHz could be administrated on treating malignant melanoma tumor...
December 2016: Clinical and Translational Medicine
F Grosso, J Mądrzak, L Crinò, A Chella, U Weinberg, G L Ceresoli
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
U Weinberg, O Farber, Z Bomzon, M Giladi, E D Kirson
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
U Weinberg, O Farber, M Giladi, Z Bomzon, E D Kirson
No abstract text is available yet for this article.
April 2016: Journal of Thoracic Oncology
Suyash Mohan, Sanjeev Chawla, Sumei Wang, Gaurav Verma, Aaron Skolnik, Steven Brem, Katherine B Peters, Harish Poptani
Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis...
July 2016: CNS Oncology
Wolfgang Wick
No abstract text is available yet for this article.
March 2016: Neuro-oncology
George Ansstas, David D Tran
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy approved in the United States for newly diagnosed and recurrent GBM. This would reserve bevacizumab for subsequent disease progression. In this case series, we describe 8 patients with recurrent GBM who had disease progression on bevacizumab, discontinued bevacizumab treatment, and were treated with TTFields therapy alone...
January 2016: Case Reports in Neurology
Cornelia Wenger, Ricardo Salvador, Peter J Basser, Pedro C Miranda
PURPOSE: To investigate tumors of different size, shape, and location and the effect of varying transducer layouts on Tumor Treating Fields (TTFields) distribution in an anisotropic model. METHODS AND MATERIALS: A realistic human head model was generated from MR images of 1 healthy subject. Four different virtual tumors were placed at separate locations. The transducer arrays were modeled to mimic the TTFields-delivering commercial device. For each tumor location, varying array layouts were tested...
April 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Kenneth D Swanson, Edwin Lok, Eric T Wong
As with many cancer treatments, tumor treating fields (TTFields) target rapidly dividing tumor cells. During mitosis, TTFields-exposed cells exhibit uncontrolled membrane blebbing at the onset of anaphase, resulting in aberrant mitotic exit. Based on these criteria, at least two protein complexes have been proposed as TTFields' molecular targets, including α/β-tubulin and the septin 2, 6, 7 heterotrimer. After aberrant mitotic exit, cells exhibited abnormal nuclei and signs of cellular stress, including decreased cellular proliferation and p53 dependence, and exhibit the hallmarks of immunogenic cell death, suggesting that TTFields treatment may induce an antitumor immune response...
January 2016: Current Neurology and Neuroscience Reports
Cornelia Wenger, Moshe Giladi, Ze'ev Bomzon, Ricardo Salvador, Peter J Basser, Pedro C Miranda
Effects of electric fields on biological cells have been extensively studied but primarily in the low and high frequency regimes. Low frequency AC fields have been investigated for applications to nerve and muscle stimulation or to examine possible environmental effects of 60 Hz excitation. High frequency fields have been studied to understand tissue heating and tumor ablation. Biological effects at intermediate frequencies (in the 100-500 kHz regime) have only recently been discovered and are now being used clinically to disrupt cell division, primarily for the treatment of recurrent glioblastoma multiforme...
2015: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"